Atossa Therapeutics Files 8-K/A Amendment
Ticker: ATOS · Form: 8-K/A · Filed: Apr 2, 2024 · CIK: 1488039
Sentiment: neutral
Topics: amendment, financial-reporting, sec-filing
TL;DR
Atossa Therapeutics filed an amendment to its 8-K, updating financial statements and exhibits.
AI Summary
Atossa Therapeutics, Inc. filed an 8-K/A on April 1, 2024, to amend its previous filing regarding financial condition and results of operations. The amendment pertains to the financial statements and exhibits, indicating a correction or addition to previously reported information. The company is incorporated in Delaware and its principal executive offices are located at 107 Spring Street, Seattle, Washington.
Why It Matters
This filing indicates a necessary update or correction to Atossa Therapeutics' financial reporting, which could impact investor understanding of the company's financial health and operational results.
Risk Assessment
Risk Level: low — This is a routine amendment to a previous filing, not indicating new negative events.
Key Players & Entities
- Atossa Therapeutics, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- 107 Spring Street, Seattle, Washington 98104 (address) — Principal Executive Offices
- April 1, 2024 (date) — Date of earliest event reported
FAQ
What specific financial statements or exhibits were amended in this 8-K/A filing?
The filing indicates an amendment to 'Financial Statements and Exhibits' but does not specify which particular statements or exhibits were changed in the provided text.
What was the original filing date that this 8-K/A is amending?
The filing is an amendment to a previous report, and the 'Date of earliest event reported' is April 1, 2024, suggesting it amends a filing related to events around that date.
What is the primary business of Atossa Therapeutics, Inc.?
Atossa Therapeutics, Inc. is in the 'Pharmaceutical Preparations' industry, SIC code 2834.
What is the SEC file number for Atossa Therapeutics, Inc.?
The SEC file number for Atossa Therapeutics, Inc. is 001-35610.
Where are Atossa Therapeutics, Inc.'s principal executive offices located?
The principal executive offices of Atossa Therapeutics, Inc. are located at 107 Spring Street, Seattle, Washington 98104.
Filing Stats: 634 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2024-04-01 19:18:55
Key Financial Figures
- $0.18 — ge on which registered Common Stock , $0.18 par value ATOS The Nasdaq Capital M
Filing Documents
- atos-20240401.htm (8-K/A) — 49KB
- atos-ex99_1.htm (EX-99.1) — 194KB
- 0000950170-24-039634.txt ( ) — 370KB
- atos-20240401.xsd (EX-101.SCH) — 27KB
- atos-20240401_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On April 1, 2024, Atossa Therapeutics, Inc. (the "Company") issued a press release announcing the year ended December 31, 2023 financial results and providing a Company update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Items 2.02 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be " filed " for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated April 1, 2024 (Corrected) 104 Cover page Interactive Data File (embedded within the Inline XBRL document) * * *
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Atossa Therapeutics, Inc. Date: April 1, 2024 By: /s/ Heather Rees Heather Rees Senior Vice President, Finance & Accounting